GSK reports Q1 core EPS 46.5p, up 9% at CER

Reports total Q1 sales GBP 7.6B +2% AER; +5% CER. Luke Miels, CEO, said, “GSK (GSK) has made a strong start to 2026, with good performance from our key growth drivers. Alongside operational delivery, we are focused on execution and accelerating R&D. This is visible in filings we have achieved for bepirovirsen, our potential functional cure for hepatitis B; updated phase III plans for our oncology ADCs; and completed acquisitions for new pipeline assets: ozureprubart for food allergies, and HS235 for pulmonary hypertension.”